Welcome To RobinsPost.com


Related News Videos From Youtube For:

3 Biggest Healthcare Stories At #JPM19 This Year

Every year, thousands descend upon San Francisco from all over the world to hear the latest corporate updates from healthcare's most important companies. The event, which is organized by J.P. Morgan, is often used to unveil market-moving news and this year's conference was no disappointment: Bristol-Myers Squibb (NYSE: BMY) announced a mega-deal for biotech Goliath Celgene (NASDAQ: CELG). Eli Lilly (NYSE: LLY) acquired precision-cancer drug developer Loxo Oncology (NASDAQ: LOXO) for $8 billion. And Sage Therapeutics (NASDAQ: SAGE) rolled out impressive data for a postpartum depression drug. In this episode of The Motley Fool's Industry Focus: Healthcare, Todd Campbell joins analyst Shannon Jones to explain why Bristol-Myers and Loxo Oncology are doing their deals and how Sage Therapeutics hopes to reshape how doctors treat depression. Tune in to learn if Celgene's stock is still worth buying, Loxo Oncology can provide the spark Eli Lilly needs, and if Sage Therapeutics has a blockbuster drug on its hands. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool

The mathematician who cracked Wall Street | Jim Simons

Why the poorest county in West Virginia has faith in Donald Trump | Anywhere but Washington

Eli Lilly CEO: Loxo acquisition can help us treat cancer globally

Is this the Beginning of Facebook's Great Recovery?

Bristol-Myers and Celgene CEOs talk acquisition deal

The most important lesson from 83,000 brain scans | Daniel Amen | TEDxOrangeCoast

2019 WMIF | Last Mile: Fully Implementing AI in Healthcare

GSK CEO: Pfizer venture creates value for both our consumer and pharma businesses

John Bogle, Founder of The Vanguard Group | A Motley Fool Special Interview

Davos 2019 - Strategic Outlook on Healthcare